Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. [electronic resource]
Producer: 20160315ISSN:- 1460-2105
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Carcinoma, Pancreatic Ductal -- drug therapy
- Deoxycytidine -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Electrophoretic Mobility Shift Assay
- Female
- Gene Expression Regulation, Neoplastic
- Gene Knockdown Techniques
- Germ-Line Mutation
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Oxidoreductases -- genetics
- Pancreatic Neoplasms -- drug therapy
- Polymorphism, Single Nucleotide
- Predictive Value of Tests
- Prognosis
- Sp Transcription Factors -- genetics
- Treatment Outcome
- Tumor Suppressor Proteins -- genetics
- WW Domain-Containing Oxidoreductase
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.